SenesTech Expands its Rapidly Growing Global Footprint and Clears Major Regulatory Hurdle, Paving the Way for Use in Australia and New Zealand

Rhea-AI Summary

SenesTech (NASDAQ: SNES) announces expansion into New Zealand and Australia markets with its Evolve™ rodent fertility control solution. The company expects regulatory approval in New Zealand by Q3 2025, with shipments beginning in late Q2 or early Q3. Through partnership with Evicom, SenesTech aims to integrate into New Zealand's Predator Free 2050 initiative, a $4.5 billion conservation program.

The expansion targets Australia's growing rodent pest control market, currently valued at $100 million and growing 5% annually. SenesTech projects regional annual demand for Evolve to reach or exceed $500,000. The product offers a non-lethal alternative to traditional rodenticides, addressing environmental concerns while maintaining effectiveness in pest management.

Positive

• Expected regulatory approval in New Zealand by Q3 2025
• Partnership with Evicom for distribution in Australia/NZ
• Access to $4.5B New Zealand Predator Free 2050 program
• Entry into $100M Australian market growing at 5% annually
• Projected regional demand of $500,000+ annually

Negative

• Regulatory approval still pending
• Revenue generation delayed until Q3 2025
• Market penetration yet to be proven in new territories

Insights

Biotech Market Analyst

SenesTech's Australian/New Zealand Expansion: Strategic Market Entry with Significant Revenue Potential

SenesTech's regulatory progress in New Zealand represents a strategic entry into markets actively seeking alternatives to traditional rodenticides. The company's Evolve™ fertility control products address a critical gap in the $100 million Australian rodent control market (growing at 5%+ annually) and New Zealand's $4.5 billion Predator Free 2050 initiative.

What makes this particularly noteworthy is the scale of opportunity relative to SenesTech's current $3.3 million market capitalization. The projected $500,000 in regional annual demand could substantially impact the company's revenue trajectory if realized. However, investors should note the extended timeline – with regulatory approval expected in Q3 2025 and initial shipments beginning late Q2 or early Q3 – meaning material revenue contribution won't occur until late 2025 or 2026.

The partnership with Evicom provides important distribution infrastructure and established relationships with government conservation programs and commercial pest control operators. This addresses a key challenge for small companies entering international markets: building sales channels and regulatory expertise.

From a competitive standpoint, SenesTech's fertility control approach occupies a unique position in a market dominated by traditional toxicants. The timing aligns with increasing regulatory pressure on conventional rodenticides due to secondary poisoning concerns and environmental impact. Both Australia and New Zealand have stringent environmental protection policies that favor non-toxic alternatives.

The technology's alignment with New Zealand's conservation goals is particularly compelling. Traditional poisons have effectiveness in sensitive ecosystems where protecting native species is paramount. Fertility control offers a sustainable approach to managing invasive rodent populations without the ecological side effects of toxicants.

While the market opportunity is substantial, execution risks remain. Government procurement cycles are notoriously long, adoption of novel technologies requires education and proof-of-concept demonstrations, and international expansion strains resources for micro-cap companies. The projected demand will require SenesTech to scale production and support capabilities accordingly.

This expansion represents a potential inflection point for SenesTech if successfully executed, opening a pathway to other conservation-focused markets globally while establishing credibility for the fertility control approach as a mainstream pest management solution.

SenesTech and Distribution Partner to Bring Evolve™ to New Zealand's Predator Free 2050 Initiative

PHOENIX, Feb. 25, 2025 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), a pioneer in fertility control solutions for managing rodent populations, is pleased to announce a significant milestone in its expansion into vast and largely untapped markets for rodent fertility control across New Zealand and Australia. In partnership with Evicom, a provider of environmental consulting, on-ground environmental management and wildlife control and management services across Australia and New Zealand, SenesTech is bringing Evolve™ Rat and Evolve™ Mouse to the forefront of integrated pest management (IPM) solutions in the region.

Following the submission of Evolve for regulatory approval in New Zealand, the company anticipates final approval in the third quarter of 2025, with stocking shipments beginning as early as late second quarter or early third quarter. This approval marks a transformational step in the way rodent populations are managed, offering a solution that is not only highly effective but also aligns with the strong environmental and ecological priorities of New Zealand and Australia.

Unlocking a Sustainable and Humane Alternative for Rodent Control 

Rodent overpopulation remains a major ecological and economic challenge in both countries, threatening native wildlife, agriculture, and urban environments. Traditional rodenticides, while effective in the short term, pose significant risks to non-target species, the food chain, and the broader ecosystem. By contrast, Evolve is a revolutionary birth control solution that restricts rodent reproduction at its source, offering a non-lethal, environmentally responsible alternative that seamlessly integrates into existing IPM strategies.

A Perfect Fit for New Zealand's Predator Free 2050 Vision 

New Zealand's Predator Free 2050 initiative is one of the most ambitious conservation programs in the world, aiming to eradicate invasive predators such as rats, stoats, and possums to safeguard native species. New Zealand expects to spend over $4.5 billion on this program, explicitly counting on advancements in technology and the development of more efficient and effective eradication methods to accomplish their goals. Evolve represents an ideal partner for this effort, as it reduces rat populations without the collateral damage of poisons, preserving biodiversity and delicate ecosystems in line with New Zealand's conservation goals.

Expansion Opportunities in Australia's Growing Market 

Beyond New Zealand, Australia presents another major growth opportunity. It is estimated that Australia currently spends $100 million on rodent pest control annually, with the spend growing at over 5% per year. With escalating concerns over rodent infestations in ecologically sensitive habitat, agricultural, commercial, and urban settings, the adoption of sustainable pest management solutions is a rising priority. Evolve's environmental safety, ease of integration, and long-term efficacy position it as a game-changing solution for both government-backed conservation programs and private sector pest control initiatives.

A Market Poised for Rapid Growth 

"By expanding into New Zealand and Australia we are delivering on our strategy to become the global leader in humane and sustainable fertility control solutions for managing rat populations, while tapping into significant, high-growth markets that are actively seeking sustainable, humane, and effective alternatives to traditional rodenticides," said Joel Fruendt, President and CEO of SenesTech. "Evolve reduces reliance on poisons, aligning with changing regulatory standards and environmental policies. This is especially crucial for New Zealand, where protecting native wildlife is a national priority, and for Australia, where large-scale agricultural and urban pest control efforts demand more responsible solutions."

With Evicom's broad network and strong government and private sector partnerships, SenesTech expects the regional annual demand for Evolve Rodent Birth Control to rapidly reach or exceed $500,000, further solidifying its position as a leader in innovative pest control solutions.

About SenesTech, Inc.
SenesTech is committed to creating healthier environments by humanely managing animal pest populations through fertility control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are humane, effective, and sustainable.

For more information, visit https://senestech.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, our anticipation of final regulatory approval in New Zealand for Evolve in the third quarter of 2025; our anticipation of stocking shipments to begin in New Zealand as early as late second quarter or early third quarter of 2025; our belief that the regulatory approval in New Zealand is a transformational step in the way rodent populations are managed; our belief that Evolve is a solution that is highly effective and aligns with the strong environmental and ecological priorities of New Zealand and Australia; our belief that Evolve is a non-lethal, environmentally responsible alternative that seamlessly integrates into IPM strategies; our belief that Evolve is a perfect fit for New Zealand's Predator Free 2050 vision; our belief that New Zealand's Predator Free 2050 initiative is one of the most ambitious conservation programs in the world; our believe that Evolve represents an ideal partner for New Zealand's Predator Free 2050 initiative; our belief that Australia presents a major growth opportunity; our belief that Evolve's environmental safety, ease of integration, and long-term efficacy position is a game-changing solution for both New Zealand and Australia's government-backed conservation programs and private sector pest control initiatives; our belief that by expanding into New Zealand and Australia, we are delivering on our strategy to become the global leader in humane and sustainable fertility control solutions for managing rat populations, while tapping into significant, high-growth markets that are actively seeking sustainable, humane, and effective alternatives to traditional rodenticides; our belief that because Evolve reduces the reliance on poisons, which aligns with changing regulatory standards and environmental policies, it is especially crucial for New Zealand and Australia; our expectation that the regional annual demand for Evolve to rapidly reach or exceed $500,000; and our belief that Evicom will further solidify our position as a leader in innovative pest control solutions. Forward-looking statements may describe future expectations, plans, results, or  strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; our ability to regain and maintain compliance with Nasdaq's continued listing requirements; regulatory approval and regulation of our products; and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Investor Contact:
Robert Blum, Lytham Partners, LLC
(602) 889-9700, senestech@lythampartners.com 

Marketing Contact:
Rochelle Paulet, SenesTech, Inc.
(928) 779-4143, marketing@senestech.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-expands-its-rapidly-growing-global-footprint-and-clears-major-regulatory-hurdle-paving-the-way-for-use-in-australia-and-new-zealand-302384771.html

SOURCE SenesTech, Inc.

FAQ

When will SenesTech (SNES) begin shipping Evolve to New Zealand?

SenesTech expects to begin shipping Evolve to New Zealand in late Q2 or early Q3 2025, following anticipated regulatory approval in Q3 2025.

What is the market size for SNES Evolve products in Australia?

Australia's rodent pest control market is valued at $100 million, growing at 5% annually, with SNES projecting regional demand of $500,000+ for Evolve.

How does SNES Evolve align with New Zealand's Predator Free 2050 initiative?

Evolve provides a non-lethal, environmentally safe fertility control solution that supports the $4.5B Predator Free 2050 initiative's goal of eradicating invasive predators.

Who is SenesTech's distribution partner for Evolve in Australia and New Zealand?

Evicom, a provider of environmental consulting and wildlife control services across Australia and New Zealand.

What distinguishes SNES Evolve from traditional rodent control methods?

Evolve is a non-lethal birth control solution that restricts rodent reproduction without the environmental risks associated with traditional rodenticides.